Document |
Document Title |
WO/2024/034644A1 |
The present invention provides a compound for treating or preventing reduced intracellular ATP levels. The present invention relates to a compound represented by formula (I) or a pharmaceutically acceptable salt or solvate thereof, and...
|
WO/2024/033293A1 |
The present invention relates to acylhydrazides obtained in situ by enzymatic hydrolysis of the parent prodrug 2-(difluoromethyl)- or 2-(trifluoromethyl)-1,3,4- oxadiazole, in histone deacetylase 6 (HDAC6).
|
WO/2024/032501A1 |
Provided are a compound of formula 0, a stereoisomer thereof, a tautomer thereof, a geometric isomer thereof, an enantiomer thereof, a diastereomer thereof, a racemate thereof, a polymorph thereof, a solvate thereof, a hydrate thereof, a...
|
WO/2024/033479A1 |
The application relates to compounds of formula (B1A), (B1B), (B1C) or a salt, a solvate, a hydrate, a polymorph, a tautomer, a racemate or a stereoisomer thereof, to pharmaceutical compositions comprising such a compound, and to the com...
|
WO/2024/032530A1 |
Provided are an aromatic heterocyclic cyclohexyl aminoalkyl piperidine derivative, a preparation method and a use thereof. Specifically, provided are a compound of formula (I), a stereoisomer thereof, a tautomer thereof or a pharmaceutic...
|
WO/2024/035194A1 |
The present invention relates to a novel heteroaryl-substituted derivative and a composition for preventing or treating neurodegenerative diseases, cancer, and inflammatory diseases comprising same. The heteroaryl-substituted derivative ...
|
WO/2024/036226A1 |
Provided herein is a method for treating autism or autism spectrum disorders. The method comprises identifying a subject and treating the subject with expanded natural killer cells (NKs). Also provided is a composition for treating autis...
|
WO/2024/035268A2 |
Pharmaceutical compositions and methods for treating tauopathies are provided.
|
WO/2024/033539A1 |
The present disclosure provides cannabinoid drug substances, pharmaceutical compositions and methods of treating neurological or neurodegenerative disorders in a human patient.
|
WO/2024/033895A2 |
The present disclosure relates to antisense oligonucleotides, which target IDO1 mRNA in a cell, leading to reduced expression of IDO1 protein. Reduction of IDO1 protein expression is beneficial for the treatment of certain medical disord...
|
WO/2024/033459A1 |
The present invention relates to pharmaceutical compositions comprising 5-ethyl-4- methyl-N-[4-[(2S) morpholin-2-yl]phenyl]-1H-pyrazole-3-carboxamide (ralmitaront), to processes for their preparation and their use in medical treatment.
|
WO/2024/031889A1 |
The present invention relates to the field of biotechnology, and specifically, to use of a gene delivery system in delivering a gene to microglial cells, or in preparing a reagent for delivering a gene to microglial cells. The gene deliv...
|
WO/2024/032390A1 |
Provided are a macrocyclic triazole compound represented by formula I or an isotope labeled compound thereof, or an optical isomer, a geometric isomer, a tautomer or an isomer mixture thereof, or a pharmaceutically acceptable salt, or a ...
|
WO/2024/032507A1 |
Provided are a metal-phospholipid complex, a metal-phospholipid complex particle, a drug-lipid particle, a method for preparing same, and use thereof, which relate to the field of biotechnology. The metal-phospholipid complex is formed b...
|
WO/2024/034424A1 |
[Problem] The purpose of the present invention is to provide a novel composition for enhancing motivation and/or a composition for improving wakefulness upon getting out of bed. [Solution] The aforementioned problem is solved by a compos...
|
WO/2024/035613A1 |
Provided herein are compositions and methods for treating and/or ameliorating the FOXG1 syndrome or the symptoms associated therewith. The compositions and methods disclosed herein utilize antisense oligonucleotides that target long non-...
|
WO/2024/030332A1 |
The present disclosure relates to methods for treating a neurological disorder, such as Parkinson's Disease (PD), progressive supranuclear palsy (PSP), amyotrophic lateral sclerosis (ALS), and Alzheimer's Disease. The methods include adm...
|
WO/2024/029755A1 |
The present invention relates to an animal model of Charcot-Marie-Tooth disease caused by K141N or K141T mutations in HSPB8. In this animal model expressing the K141N or K141T mutant HSPB8 protein, symptoms of Charcot-Marie-Tooth disease...
|
WO/2024/029239A1 |
The purpose of the present invention is to provide a novel affective disorder ameliorating agent. A PKCγ activity inhibitor is useful as an active ingredient for an affective disorder ameliorating agent.
|
WO/2024/029489A1 |
Provided herein are compounds and compositions useful in inhibiting a receptor tyrosine kinase, KIT. The compounds and compositions provided herein are useful for the prevention or treatment of one or more KIT mediated diseases or cond...
|
WO/2024/026574A1 |
The present application relates to 3-cyclic amine-indole dimers of general Formula (I), to processes for their preparation, to compositions comprising them and to their use in activation of a serotonin receptor in a cell, as well as to t...
|
WO/2024/030627A1 |
Provided herein are compounds having a structure of formula (A), or pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4, Rd, and n are described herein. Also provided herein are compositions comprising compounds of Formula ...
|
WO/2024/029992A1 |
The present invention relates to a peptide capable of directly binding to amyloid beta protein Aβ42, which is known to be a causative agent of Alzheimer's disease, and a composition for the treatment and prevention of Alzheimer's diseas...
|
WO/2024/031053A1 |
Provided herein are TDP-43 variants in which a prion-like domain (PLD) of the TDP-43 variant is mutated to have more aromatic amino acids and/or aromatic amino acids that are more evenly spaced than in a PLD from a wild type TDP-43, nucl...
|
WO/2024/029242A1 |
Disclosed is a linear peptide or cyclic peptide having an amino acid sequence represented by formula (1): XN-X5-X6-X7-X8-X9-X10-X11-X12-X13-X14-X15 (1), or a pharmacologically acceptable salt thereof. Binding this peptide to LRP1 makes i...
|
WO/2024/028483A1 |
The present invention relates to brain derived nerve factor (BDNF) for use in the prevention or treatment of sensorineural hearing loss in a subject, wherein said BDNF is administered intranasally to said subject.
|
WO/2024/028779A1 |
Provided herein are vaporizer formulations comprising fungal material from Amanita muscaria and/or an extract thereof, as well as devices comprising the same. Also provided are methods of using the disclosed formulations and devices to m...
|
WO/2024/030628A1 |
The present invention provides deuterium-enriched compounds, compositions thereof, and methods of using the same.
|
WO/2024/026573A1 |
The present application relates to 3-ethylamino-indole dimers of general Formula I, to processes for their preparation, to compositions comprising them and to their use in activation of a serotonin receptor in a cell, as well as to treat...
|
WO/2024/028349A2 |
The present invention relates to levodopa for preventing the development of addiction and/or dependence to prescribed stimulants in a subject treated with stimulants. The present invention also relates to the use of a composition, pharma...
|
WO/2024/028495A1 |
The present invention relates generally to substituted ergoline compounds and compositions, more particularly new lysergamide derivatives and compositions, and applications of these. The invention furthermore relates to a new production ...
|
WO/2024/028487A1 |
The present invention relates to nerve growth factor (NGF) or a mutein thereof for use in the prevention or treatment of sensorineural hearing loss in a subject, wherein said NGF is administered intranasally to said subject.
|
WO/2024/030504A1 |
The invention provides methods of treating patients with Parkinson's disease (PD) associated with wild-type LRRK2. The invention recognizes that analysis of biomarkers in such patients allows identification of those patients who will res...
|
WO/2024/026568A1 |
Disclosed are novel fused heterocyclic mescaline derivative compounds, notably fused heterocyclic mescaline derivatives and pharmaceutical and recreational drug formulations containing the same. Methods of making and using these compound...
|
WO/2024/028808A1 |
The present disclosure relates to compounds of Formula (I) which modulate the activity of protein phosphatase 2A (PP2A). The compounds of the present disclosure are useful in treating, preventing, and/or ameliorating cancer, diabetes, au...
|
WO/2024/027723A1 |
Disclosed in the present invention are a crystal form, a salt type and a composition of a pyridazine compound and a preparation method therefor, and specifically disclosed are a method for preparing a crystal form A and a composition of ...
|
WO/2024/029638A1 |
The present invention relates to a series of novel heterocyclyl-phenyl-methylamine derivatives, a preparation method therefor, and a use thereof for prevention, alleviation, or treatment of multiple sclerosis.
|
WO/2024/028731A1 |
Provided are novel multispecific antibodies comprising at least one of a first antigen-binding region and a second antigen-binding region each capable of binding specifically to human epidermal growth factor receptor 2 (HER2), and a thir...
|
WO/2024/029678A1 |
The present invention relates to a use of PDH inhibitors in the treatment of neurodegenerative diseases, and according to the present invention, in a DJ-1 deletion Parkinson's disease Drosophila model, by activation of PDK, promotion of ...
|
WO/2024/029535A1 |
The present invention provides a polypeptide that specifically recognizes a structurally abnormal protein caused by misfolding, etc. in mammals, and a detection agent and a reduction agent for a structurally abnormal protein with the use...
|
WO/2024/027752A1 |
Provided are a pharmaceutical composition comprising a heterocyclic compound, a preparation method therefor, and use thereof. Further provided is a pharmaceutical composition Q, comprising a substance X and a pharmaceutical excipient, th...
|
WO/2024/027751A1 |
Disclosed are a crystal form of a heterocyclic compound, a preparation method therefor, and the use thereof. The heterocyclic compound is the compound represented by formula I. For the crystal form thereof, the X-ray powder diffraction p...
|
WO/2024/030560A2 |
Power equipment includes a chassis, an implement coupled to the chassis, and a battery system coupled to the chassis. The battery system includes a first battery pack, a second battery pack, a circuit including a first switch configured ...
|
WO/2024/029995A1 |
The present invention relates to a peptide capable of directly binding to amyloid beta protein Aβ42, known to be a causative agent of Alzheimer's disease, and a composition for treating and preventing Alzheimer's disease, comprising the...
|
WO/2024/028516A1 |
A synthesis method for the preparation of a cannabinoid selected from cannabidiol (CBD) and Δ9-tetrahydrocannabinol (THC), comprising the steps of: a) dissolving olivetol in dichloromethane (DCM) with stirring; b) adding FeCl3 * 6H2O as...
|
WO/2024/028611A1 |
The present invention provides for an effective pharmacological therapy for obsessive compulsive disorder.
|
WO/2024/029962A1 |
The present invention relates to use of a novel PPAR activity modulator for the prevention, amelioration or treatment of degenerative brain diseases and, more specifically, provides a composition for the prevention, amelioration or treat...
|
WO/2024/029630A1 |
The present disclosure provides a cyclic peptide derivative, a method for producing the same, and a composition. The present disclosure pertains to a compound for neural cell activity regulation. More specifically, the compound of the pr...
|
WO/2024/028732A1 |
Provided are novel multispecific antibodies comprising at least one of a first antigen-binding region and a second antigen-binding region each capable of binding specifically to human epidermal growth factor receptor 2 (HER2), and a thir...
|
WO/2024/027800A1 |
The present invention relates to a new compound as a 5-HT2A receptor inverse agonist, a preparation method therefor and a pharmaceutical composition. The present invention further relates to the use of the compound or the pharmaceutical ...
|